**Supplementary data**

# TP-CSO: a Triptolide Prodrug for Pancreatic Cancer Treatment

Xinlong Wang[1,2], Huahui Zeng[2], Xin Zhu[1], Duanjie Xu[1], Qikang Tian[1], Can Wang[1], Lingzhou Zhao[3], Junwei Zhao[4], Mingsan Miao[1,2,*] and Xiangxiang Wu[1,2,*]

[1] Pharmacy College, Henan University of Chinese Medicine, Zhengzhou 450046, China

[2] Academy of Chinese Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China

[3] Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China

[4] Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China

* Correspondence: wuxx-415@126.com; miaomingsan@163.com; Tel.: +86-0371-65680206





Figure S1: $^{1}$H NMR spectra of TPS, CSO and TP-CSO





Figure S2: Standard curve for TP




Figure S3: HPLC spectra of TP weight percentage in TP-CSO (sig=218, 4)